MX2017009336A - Polinucleótidos dirigidos al sistema nervioso central. - Google Patents

Polinucleótidos dirigidos al sistema nervioso central.

Info

Publication number
MX2017009336A
MX2017009336A MX2017009336A MX2017009336A MX2017009336A MX 2017009336 A MX2017009336 A MX 2017009336A MX 2017009336 A MX2017009336 A MX 2017009336A MX 2017009336 A MX2017009336 A MX 2017009336A MX 2017009336 A MX2017009336 A MX 2017009336A
Authority
MX
Mexico
Prior art keywords
nervous system
central nervous
targeting polynucleotides
system targeting
polynucleotides
Prior art date
Application number
MX2017009336A
Other languages
English (en)
Inventor
Philip KELLS Adrian
Zhou Pengcheng
Hou Jinzhao
Wen-Yee Sah Dinah
Goulet Martin
RAMAMOORTHI Kartik
Shu Yanqun
Robert Stewart Gregory
Original Assignee
Voyager Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Voyager Therapeutics Inc filed Critical Voyager Therapeutics Inc
Publication of MX2017009336A publication Critical patent/MX2017009336A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se relaciona con composiciones y métodos para la preparación, fabricación y uso terapéutico de polinucleótidos que codifican cargas para el tratamiento de trastornos del SNC.
MX2017009336A 2015-01-16 2016-01-15 Polinucleótidos dirigidos al sistema nervioso central. MX2017009336A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562104101P 2015-01-16 2015-01-16
US201562152185P 2015-04-24 2015-04-24
US201562152283P 2015-04-24 2015-04-24
US201562159888P 2015-05-11 2015-05-11
US201562159882P 2015-05-11 2015-05-11
PCT/US2016/013671 WO2016115503A1 (en) 2015-01-16 2016-01-15 Central nervous system targeting polynucleotides

Publications (1)

Publication Number Publication Date
MX2017009336A true MX2017009336A (es) 2017-11-15

Family

ID=56406481

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017009336A MX2017009336A (es) 2015-01-16 2016-01-15 Polinucleótidos dirigidos al sistema nervioso central.
MX2022003323A MX2022003323A (es) 2015-01-16 2017-07-17 Polinucleotidos dirigidos al sistema nervioso central.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022003323A MX2022003323A (es) 2015-01-16 2017-07-17 Polinucleotidos dirigidos al sistema nervioso central.

Country Status (7)

Country Link
US (2) US20180021364A1 (es)
EP (2) EP3632923A1 (es)
AU (2) AU2016206478A1 (es)
CA (1) CA2970730A1 (es)
HK (1) HK1246815A1 (es)
MX (2) MX2017009336A (es)
WO (1) WO2016115503A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017006216A (es) 2014-11-14 2018-08-29 Voyager Therapeutics Inc Composiciones y métodos para tratar la esclerosis lateral amiotrófica (ela).
DK3218386T3 (da) 2014-11-14 2021-06-07 Voyager Therapeutics Inc Modulatorisk polynukleotid
WO2016172659A1 (en) * 2015-04-24 2016-10-27 University Of Florida Research Foundation, Inc. Aav vector for treatment of friedreich's ataxia
CA3002406A1 (en) * 2015-10-29 2017-05-04 Voyager Therapeutics, Inc. Delivery of central nervous system targeting polynucleotides
LT3411484T (lt) * 2016-02-05 2023-11-27 Emory University Viengrandžio arba sau pačiam komplementaraus adeno-asocijuoto viruso 9 injekcija į smegenų skystį
IL302748A (en) 2016-05-18 2023-07-01 Voyager Therapeutics Inc modulatory polynucleotides
CN109831916B (zh) 2016-05-18 2023-07-21 沃雅戈治疗公司 治疗亨廷顿氏舞蹈病的组合物和方法
MX2019005235A (es) * 2016-11-09 2019-12-05 Intrexon Corp Constructos de expresion de frataxina.
US11752181B2 (en) 2017-05-05 2023-09-12 Voyager Therapeutics, Inc. Compositions and methods of treating Huntington's disease
CN110913866A (zh) 2017-05-05 2020-03-24 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
EP3662060A2 (en) 2017-08-03 2020-06-10 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
EP3684388A4 (en) * 2017-09-22 2021-09-22 Voyager Therapeutics, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF HUNTINGTON'S DISEASE
AU2018338728A1 (en) * 2017-09-29 2020-04-16 Centre National De La Recherche Scientifique (Cnrs) Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery
US20200237799A1 (en) 2017-10-16 2020-07-30 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
JP7502991B2 (ja) 2017-10-16 2024-06-19 ボイジャー セラピューティクス インコーポレイテッド 筋萎縮性側索硬化症(als)の治療
ES2951945T3 (es) * 2017-10-17 2023-10-25 Fundacio Inst Dinvestigacio En Ciencies De La Salut Germans Trias I Pujol Vectores para el tratamiento de ataxia de Friedreich
JP7406677B2 (ja) 2018-04-03 2023-12-28 ギンコ バイオワークス インコーポレイテッド 抗体を回避するウイルスベクター
WO2020069461A1 (en) * 2018-09-28 2020-04-02 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
WO2020106916A1 (en) * 2018-11-21 2020-05-28 Stridebio, Inc. Recombinant viral vectors and nucleic acids for producing the same
TW202102525A (zh) 2019-03-21 2021-01-16 美商史崔德生物公司 重組腺相關病毒載體
MX2021013266A (es) * 2019-04-29 2021-11-17 Univ Pennsylvania Nuevas capsides de aav y composiciones que las contienen.
MX2021015076A (es) * 2019-06-10 2022-06-02 Homology Medicines Inc Composiciones de virus adeno-asociados para transferencia del gen de la enzima lisosomal arilsulfatasa-a (arsa) y metodos de uso de las mismas.
EP4028027A4 (en) * 2019-09-13 2023-11-01 Lacerta Therapeutics, Inc COMPOSITIONS AND METHODS FOR TREATING FRIEDREICH AAXIA
GB201913974D0 (en) * 2019-09-27 2019-11-13 King S College London Vector
TW202128736A (zh) 2019-10-17 2021-08-01 美商史崔德生物公司 用於治療c型尼曼—匹克病之腺相關病毒載體
AU2020405149A1 (en) * 2019-12-19 2022-07-07 The Trustees Of The University Of Pennsylvania Compositions for treating Friedreich's ataxia
JP2023535632A (ja) 2020-07-27 2023-08-18 アンジャリウム バイオサイエンシズ エージー Dna分子の組成物、その作製方法、及びその使用方法
WO2023073526A1 (en) 2021-10-25 2023-05-04 Novartis Ag Methods for improving adeno-associated virus (aav) delivery

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
US5741657A (en) 1995-03-20 1998-04-21 The Regents Of The University Of California Fluorogenic substrates for β-lactamase and methods of use
US7931642B2 (en) 1998-09-18 2011-04-26 Codman Neuro Sciences Sarl Infusion pump comprising a computer for calculating the respective maximum permissible dosage
US6755814B2 (en) 1999-05-26 2004-06-29 Codman Neuro Sciences Sarl Implantable infusion pump with level measurement
US7366561B2 (en) 2000-04-07 2008-04-29 Medtronic, Inc. Robotic trajectory guide
AU2001255575B2 (en) 2000-04-28 2006-08-31 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
US6549803B1 (en) 2000-05-08 2003-04-15 Image-Guided Neurologics Inc. Method and apparatus for targeting material delivery to tissue
US6464662B1 (en) 2000-07-26 2002-10-15 Image-Guided Neurologics, Inc. Drug delivery and catheter systems, apparatus and processes
US6572579B1 (en) 2000-09-13 2003-06-03 Image-Guided Neurologics, Inc. Drug delivery and catheter systems, apparatus and processes
EP2385123B1 (en) 2001-09-28 2018-04-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Microrna molecules
ATE520707T1 (de) 2001-11-13 2011-09-15 Univ Pennsylvania Verfahren für den nachweis und/oder die identifikation von sequenzen des adeno- assoziierten virus (aav) sowie isolation von dadurch identifizierten, neuen sequenzen
ES2526341T3 (es) 2001-12-17 2015-01-09 The Trustees Of The University Of Pennsylvania Secuencias de serotipo 9 de virus adeno-asociado (AAV), vectores que las contienen, y usos de las mismas
EP2359869B1 (en) 2001-12-17 2018-12-26 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same and uses therefor
US7715902B2 (en) 2002-09-12 2010-05-11 Brainlab Ag Determining distribution for planning an infusion
US6691948B1 (en) 2003-04-10 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy High torque rocket nozzle
US7683036B2 (en) 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
US7848543B2 (en) 2004-02-05 2010-12-07 Brainlab Ag Method and system for prediction and management of material and information transport in an organism
US7637897B2 (en) 2004-10-25 2009-12-29 Codman Neuro Sciences Sarl Implantable pump with integrated refill detection
EP1768041B1 (en) 2005-09-22 2016-04-13 Brainlab AG Brain tissue classification
US9101282B2 (en) 2005-09-22 2015-08-11 Brainlab Ag Brain tissue classification
US8141844B2 (en) 2005-10-26 2012-03-27 Codman NeuroSciences Sàrl Flow rate accuracy of a fluidic delivery system
US8240635B2 (en) 2005-10-26 2012-08-14 Codman Neuro Sciences Sárl Flow rate accuracy of a fluidic delivery system
US7905878B2 (en) 2005-10-31 2011-03-15 Codman & Shurtleff, Inc. Implantable pump with reservoir level detector
EP1788498A1 (en) 2005-11-21 2007-05-23 BrainLAB AG Apparatus for infusing substances
US9042958B2 (en) 2005-11-29 2015-05-26 MRI Interventions, Inc. MRI-guided localization and/or lead placement systems, related methods, devices and computer program products
US7725272B2 (en) 2006-03-30 2010-05-25 Codman Neuro Sciences, Sarl Methods and devices for monitoring fluid of an implantable infusion pump
WO2007120542A2 (en) 2006-03-30 2007-10-25 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid library and aav capsid proteins
US7998128B2 (en) 2006-05-15 2011-08-16 Therataxis, LLC. Active delivery and flow redirection: novel devices and method of delivery of materials to patients
US20100030102A1 (en) 2006-05-15 2010-02-04 David Poston Active Delivery and Flow Redirections: Novel Devices and Method of Delivery of Materials to Patients
EP1992957B1 (en) 2007-05-16 2013-01-02 BrainLAB AG Method for estimating the physiological parameters defining the edema induced upon infusion of fluid from an intraparenchymally placed catheter
WO2008144585A1 (en) 2007-05-17 2008-11-27 Medgenesis Therapeutix Inc. Convection-enhanced delivery catheter with removable stiffening member and method for using same
US9265577B2 (en) 2007-05-18 2016-02-23 The Johns Hopkins University Methods and systems for providing planning and dispensation of research and/or treatment for brain disease
US8175677B2 (en) 2007-06-07 2012-05-08 MRI Interventions, Inc. MRI-guided medical interventional systems and methods
DK2176283T3 (en) 2007-07-14 2017-02-13 Univ Iowa Res Found METHODS AND COMPOSITIONS FOR TREATMENT OF BRAIN DISEASES
US8099150B2 (en) 2007-09-24 2012-01-17 MRI Interventions, Inc. MRI-compatible head fixation frame with cooperating head coil apparatus
US8548569B2 (en) 2007-09-24 2013-10-01 MRI Interventions, Inc. Head fixation assemblies for medical procedures
EP2194906B8 (en) 2007-09-24 2015-04-22 Mri Interventions, Inc. Mri-guided medical interventional system
WO2009067205A1 (en) 2007-11-21 2009-05-28 Surgi-Vision, Inc. Methods, systems and computer program products for positioning a guidance apparatus relative to a patient
US8545405B2 (en) 2008-04-23 2013-10-01 Therataxis, Llc Device, methods, and control for sonic guidance of molecules and other material utilizing time-reversal acoustics
US8083720B2 (en) 2008-05-13 2011-12-27 Solar Matthew S Device and method for delivering therapeutic agents to an area of the body
AR076634A1 (es) 2008-11-21 2011-06-29 Medgenesis Therapeutix Inc Composiciones y metodo para tratar desordenes del sistema nervioso central
WO2010096495A1 (en) 2009-02-18 2010-08-26 The Regents Of The University Of California Device, methods, and control for sonic guidance of molecules and other material utilizing time-reversal acoustics
US8734809B2 (en) * 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
WO2012116265A2 (en) 2011-02-24 2012-08-30 MRI Interventions, Inc. Mri-guided catheters
CN102625670B (zh) 2009-06-16 2015-07-15 核磁共振成像介入技术有限公司 Mri导向装置以及能够近实时地跟踪和生成该装置的动态可视化的mri导向的介入***
US8679479B2 (en) 2009-06-29 2014-03-25 Aerase, Inc. Methods for purifying pegylated arginase
US8231563B2 (en) 2009-12-30 2012-07-31 Codman Neuro Sciences Sarl Electrokinetic actuator to titrate fluid flow
WO2011130107A2 (en) 2010-04-16 2011-10-20 Surgivision, Inc. Mri surgical systems including mri-compatible surgical cannulae for transferring a substance to and/or from a patient
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
EP2598525B1 (en) * 2010-07-28 2015-08-19 Roberto Testi Frataxin mutants
WO2012018881A2 (en) 2010-08-03 2012-02-09 Alnylam Pharmaceuticals, Inc. Methods and compositions for the regulation of rna
CN107828820B (zh) 2010-10-27 2022-06-07 学校法人自治医科大学 用于向神经***细胞导入基因的腺相关病毒粒子
US9044492B2 (en) * 2011-02-04 2015-06-02 Cellectis Sa Method for modulating the efficiency of double-strand break-induced mutagenesis
EP2500434A1 (en) 2011-03-12 2012-09-19 Association Institut de Myologie Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery
EP3881876A1 (en) 2011-08-01 2021-09-22 Alcyone Lifesciences, Inc. Microfluidic drug delivery devices
US9192393B2 (en) 2012-05-31 2015-11-24 MRI Interventions, Inc. MRI compatible surgical drills and related methods
US9031636B2 (en) 2012-07-19 2015-05-12 MRI Interventions, Inc. MRI-compatible head fixation apparatus
US9498290B2 (en) 2012-07-19 2016-11-22 MRI Interventions, Inc. Surgical navigation devices and methods
US10206693B2 (en) 2012-07-19 2019-02-19 MRI Interventions, Inc. MRI-guided medical interventional systems and methods
US9192446B2 (en) 2012-09-05 2015-11-24 MRI Interventions, Inc. Trajectory guide frame for MRI-guided surgeries
CN111621507A (zh) 2012-09-28 2020-09-04 北卡罗来纳-查佩尔山大学 靶向少突胶质细胞的aav载体
US20140243783A1 (en) 2012-10-06 2014-08-28 Raghu Raghavan Method of backflow reduction during material delivery through a needle into tissue
WO2014100157A1 (en) 2012-12-18 2014-06-26 Alcyone Lifesciences, Inc. Systems and methods for reducing or preventing backflow in a delivery system
US9066966B2 (en) * 2013-02-01 2015-06-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and pharmaceutical compositions for the treatment of cardiomyopathy due to friedreich ataxia
WO2014160092A1 (en) 2013-03-13 2014-10-02 The Children's Hospital Of Philadelphia Adeno-associated virus vectors and methods of use thereof
US9572928B2 (en) 2013-03-13 2017-02-21 MRI Interventions, Inc. Substance delivery devices, systems and methods
US9498575B2 (en) 2013-03-14 2016-11-22 MRI Interventions, Inc. Substance delivery devices, systems and methods
US20140277310A1 (en) 2013-03-15 2014-09-18 Medtronic Ardian Luxembourg S.a.r.I. Catheters Having Tethered Neuromodulation Units and Associated Devices, Systems, and Methods
US9618590B2 (en) 2013-03-15 2017-04-11 MRI Interventions, Inc. Tip assembly for MRI-compatible medical devices and MRI-compatible medical devices incorporating same
EP2970943A4 (en) * 2013-03-15 2017-04-19 The Children's Hospital of Philadelphia Vectors comprising stuffer/filler polynucleotide sequences and methods of use
CA2912678C (en) * 2013-05-15 2023-10-10 Regents Of The University Of Minnesota Adeno-associated virus mediated gene transfer to the central nervous system
WO2014189794A1 (en) 2013-05-18 2014-11-27 Medtronic Ardian Luxembourg S.A.R.L. Neuromodulation catheters with shafts for enhanced flexibility and control and associated devices, systems, and methods
US10456533B2 (en) 2013-06-17 2019-10-29 Alcyone Lifesciences, Inc. Methods and devices for protecting catheter tips and stereotactic fixtures for microcatheters
EP3027259B1 (en) 2013-07-31 2019-03-13 Alcyone Lifesciences, Inc. Systems and methods for drug delivery, treatment, and monitoring
EP3046500B1 (en) 2013-10-16 2020-08-26 ClearPoint Neuro, Inc. Surgical navigation system and related device
EP3099377B1 (en) 2014-01-27 2022-03-02 Medtronic Ireland Manufacturing Unlimited Company Neuromodulation catheters having jacketed neuromodulation elements and related devices
EP3099263A2 (en) 2014-01-27 2016-12-07 Medtronic Ardian Luxembourg S.à.r.l. Catheters with enhanced flexibility and associated devices, systems, and methods
US10595744B2 (en) 2014-02-14 2020-03-24 MRI Interventions, Inc. Surgical tool-positioning devices and related methods
US20160374743A1 (en) 2014-03-20 2016-12-29 Medtronic Ardian Luxembourg S.A.R.L. Neuromodulation catheters and related devices, systems, and methods
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
RU2020109343A (ru) * 2014-11-05 2020-03-17 Вояджер Терапьютикс, Инк. Полинуклеотиды aadc для лечения болезни паркинсона
WO2016150964A1 (en) * 2015-03-23 2016-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment and the prevention of neurological phenotype associated with friedreich ataxia
WO2016172659A1 (en) * 2015-04-24 2016-10-27 University Of Florida Research Foundation, Inc. Aav vector for treatment of friedreich's ataxia

Also Published As

Publication number Publication date
HK1246815A1 (zh) 2018-09-14
EP3632923A1 (en) 2020-04-08
WO2016115503A1 (en) 2016-07-21
US20190365793A1 (en) 2019-12-05
AU2021204620A1 (en) 2021-07-29
AU2016206478A1 (en) 2017-06-15
CA2970730A1 (en) 2016-07-21
EP3245221A1 (en) 2017-11-22
EP3245221A4 (en) 2018-06-13
US20180021364A1 (en) 2018-01-25
MX2022003323A (es) 2022-04-18

Similar Documents

Publication Publication Date Title
MX2022003323A (es) Polinucleotidos dirigidos al sistema nervioso central.
MX2018004755A (es) Entrega de polinucleotidos dirigidos al sistema nervioso central.
PH12019502793A1 (en) Aadc polynucleotides for the treatment of parkinson`s disease
MX2023010042A (es) Polinucleotidos moduladores.
MX2017005834A (es) Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
MX2023008693A (es) Polinucleotidos moduladores.
ZA202004100B (en) Diaryl macrocycles as modulators of protein kinases
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
PH12019502002A1 (en) Combination theraphy
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
MX2017011223A (es) Variantes de protoxina ii y metodos de uso.
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
MX2017012654A (es) Variantes de protoxina-ii y metodos de uso.
MX2018004220A (es) Tetrahidropiranilsulfonas sustituidas con pirazolilo.
MX2018002446A (es) Compuestos heterociclicos fusionados como moduladores s1p.
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
EP3694558A4 (en) IL-4 FUSION FORMULATIONS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) TUMORS
MX2018004217A (es) Tetrahidropiranilsulfonas sustituidas con pirazolilo.
MX2017009608A (es) Compuestos anticancerigenos.
PH12018500682A1 (en) Oxa-diazaspiro compounds having activity against pain
PH12017501872A1 (en) Methods of treating diseases
GB201520600D0 (en) Treatment of central nervous tumours
TW201612183A (en) Diaryl macrocycles as modulators of protein kinases
GB201700502D0 (en) Treatment of tumours of the central nervous system